In this study, we aim to study the differences in histological characteristics, genetic changes, access to targeted drugs, immune biomarkers, and overall prognosis between 75 patients with bone sarcoma and 70 patients with STS by using next-generation sequencing (NGS) technology in conjunction with programmed death ligand-1 (PD-L1) immunohistochemistry testing. The gene discussed is CD274; the disease is telomere syndrome.